Alnylam Pharmaceuticals ALNY currently markets four approved drugs — Onpattro, Givlaari, Oxlumo and Amvuttra — that together generated $2.99 billion in net product revenues, representing a 81% ...

CEO Neil Kumar discussed the company’s late-stage pipeline, commercial execution priorities, and the evolving transthyretin amyloid cardiomyopathy (ATTR-CM) market in a conversation with Barclays ...

JPMorgan said its survey of 28 physicians treating transthyretin amyloid cardiomyopathy, or ATTR-CM, pointed to steady uptake of BridgeBio’s drug Attruby among newly diagnosed patients and among those ...

BridgeBio stock popped Tuesday on a notable shake-up in the patent battle surrounding Pfizer's rival drug, tafamidis.

Jimmy Addison, a former Clemson University football player and a huge fan, also noticed he was short of breath when walking up the stairs in the stadium during a game.

BridgeBio Pharma Inc. BBIO is drawing renewed investor attention as the biotech company advances a slate of rare-disease therapies toward potential regulatory filings and commercial launches. William ...

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...

Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 months ago, its launch has progressed smoothly as the treatment has proven a worthy competitor to Pfizer’s powerhouse Vyndamax ...

Management expects cash burn to hold steady through 2026 and start declining by the end of next year, driven by increasing Attruby revenues and improved operating leverage. Kumar said, "Our current ...

BridgeBio Pharma (NASDAQ:BBIO) executives used the company’s fourth-quarter 2025 earnings call to highlight accelerating commercial performance for its transthyretin amyloid cardiomyopathy (ATTR-CM) d ...

$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively ...